Strides Arcolab receives US FDA approval for methoxsalen

Strides Arcolab has received approval from the United States Food & Drug Administration (US FDA) for methoxsalen capsules USP, 10 mg (soft gelatin capsules). Methoxsalen is a drug used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, clearing up the disease.
 
According to IMS data, the US market for generic methoxsalen capsule is approximately $ 13.6 million, with no generic player. The product will be manufactured at Strides Arcolab’s US FDA approved oral dosage facility at Bangalore and marketed directly by the company in the US market.